Ouabain-digoxin antagonism in rat arteries and neurones

Hong Song1, Eiji Karashima, John M Hamlyn

  • 1Department of Physiology, University of Maryland School of Medicine, 655 W. Baltimore Street, Baltimore, MD 21201, USA.  mblaustein@som.umaryland.edu or jhamlyn@umaryland.edu.

The Journal of Physiology
|December 18, 2013
PubMed

Insights

Cardiotonic steroids (CTSs) like digoxin and ouabain affect the Na+ pump, influencing blood pressure. Ouabain-like and digoxin-like CTSs can counteract each other

Area of Science:

  • Cardiovascular Pharmacology
  • Neuropharmacology
  • Cellular Physiology

Background:

  • Cardiotonic steroids (CTSs) like digoxin and ouabain are known to inhibit the Na+, K+-ATPase (Na+ pump).
  • Their effects on blood pressure are complex, with ouabain inducing hypertension and digoxin antagonizing this effect.
  • Previous understanding of CTS action was limited, necessitating further investigation into their intricate interactions.

Purpose of the Study:

  • To investigate the acute interactions between different cardiotonic steroids (CTSs) in physiological assays.
  • To elucidate the mechanisms underlying the antagonistic and synergistic effects of various CTSs on Na+ pump function.
  • To explore the therapeutic relevance of CTS interactions in cardiovascular and neuronal contexts.

Main Methods:

  • Utilized indirect assays of Na+ pump function, including myogenic tone (MT) in isolated rat mesenteric small arteries and Ca2+ signaling in cultured rat hippocampal neurons.
  • Administered various CTSs, including ouabain, digoxin, and their derivatives, individually and in combination.
  • Employed specific inhibitors like SEA0400 (Na+/Ca2+ exchanger blocker) and Rostafuroxin (a digoxigenin derivative) to probe CTS mechanisms.

Main Results:

  • Classic CTSs acted as agonists, increasing myogenic tone and augmenting Ca2+ signals.
  • CTSs were categorized into ouabain-like and digoxin-like groups, exhibiting synergistic effects within groups but antagonism between groups.
  • Digoxin-like CTSs attenuated ouabain-evoked responses, and vice versa, suggesting complex interactions at the Na+ pump level.
  • Rostafuroxin antagonized ouabain but not digoxin, while SEA0400 blocked effects of both.

Conclusions:

  • Na+ pump function involves complex interactions between different cardiotonic steroids.
  • The observed antagonism between ouabain-like and digoxin-like CTSs may involve structural changes in Na+, K+-ATPase oligomers.
  • Understanding these CTS interactions is crucial for their therapeutic application and for managing conditions influenced by Na+ pump activity.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K